UK Markets close in 7 hrs 29 mins

AdvisorShares Pure Cannabis ETF (YOLO)

NYSEArca - Nasdaq Real-time price. Currency in USD
Add to watchlist
5.61-0.20 (-3.44%)
At close: 03:52PM EDT
5.72 +0.11 (+1.96%)
After hours: 07:51PM EDT
Sign in to post a message.
  • M
    Michael
    Bottom is in boys! Just picked up 5000 shares for the long-haul going to have nice returns in 5 to 10 years good luck to all
  • g
    gitpicker
    tip toed in this morning
  • g
    goofball
    How can this be going down when more and more states are legalizing?
  • C
    CMOREGAINS
    Oh my!! YOLO just hit 6.66 in after hours. Continuing to loose my shirt. Good times!????
  • V
    Vashi
    What’s happening here!??
  • Y
    Yahoo Finance Insights
    YOLO is down 6.45% to 7.18
  • Y
    Yahoo Finance Insights
    YOLO reached a 52 Week low at 7.43
  • Y
    Yahoo Finance Insights
    YOLO reached a 52 Week low at 7.16
  • Y
    Yahoo Finance Insights
    YOLO reached a 52 Week low at 7.70
  • Y
    Yahoo Finance Insights
    YOLO is down 5.91% to 7.64
  • L
    Lauren D
    $PGEN conversation
    WSB has noticed...

    https://www.reddit.com/user/KillerB922/comments/lde8fu/feb_5th_wsb_community_pix/

    Feb 5th, WSB Community Pix...

    In search of the new GME, we have come across some tremendous opportunities which are both a combination of short squeeze plays and good underlying company. Here are out Top 3.

    - TherapeuticsMD: Ticker “TXMD”-

    Currenty trading at about $1.80, TXMD has a 1 year estimated target price from analyst of $6.83. Combined that with 25% Short Interest and Insiders and/or Institutions 73% of the float and/or tradable shares, the actual short interest is closer to 100% of the tradable float. Look for a big pop in TXMD is the short squeeze happens, if not, it will still be a 2-3X within 12 months.

    - Clovis Oncology, Inc.: Ticker “CLVS”:

    Currently trading at $8.91, CLVS is one of the top stocks on the NASDAQ. CLVS is presenting updates on their oncology(cancer) drug on February 8th. We expect good results and a squeeze to take place shortly thereafter. Institutions hold 61%+ with Blackrock recently increasing their holdings significantly. Also, 42% of the float is short so this could be a big mover next week.

    - Precigen, Inc.: Ticker “PGEN”:

    Currently trading at $7.95, Precigen may be one of the most overlooked stock and short plays in the US. The recently closed on a Public Offering of 17,250,000 @ $7.50 giving them gross proceeds of $129.4 million. Some of the biggest institutions participated in that financing, showing a lot of support in the company. 80% of the Float is owned by institutions, while insiders own another 18% or 98-99% of the float held by long term investors. With 35% of the float being short, in our opinion, the tradable float well over 100% and this could be another GME scenario as their innovative gene and cell therapies are world class. Also, they are presenting at the Guggenheim Healthcare Talks Oncology Day on Friday, February 12, 2021.

    This is not financial advice, while we believe in our Due Diligence, please do your own before you invest. If you agree with out post, please upvote it and even share it to the main WSB thread as our old account has been hacked and we had to open a new one which is not able to post until the 30-45 day period.

    Save Companies, take down the shorts. #YOLO

    KillerB - #STRENGTHINNUMBERS
  • L
    Lauren D
    $CLVS conversation
    WSB has noticed...

    Hoping for a GME run :)

    Feb 5th, WSB Community Pix:

    In search of the new GME, we have come across some tremendous opportunities which are both a combination of short squeeze plays and good underlying company. Here are out Top 3.

    - TherapeuticsMD: Ticker “TXMD”-

    Currentytrading at about $1.80, TXMD has a 1 year estimated target price from analyst of $6.83. Combined that with 25% Short Interest and Insiders and/or Institutions 73% of the float and/or tradeable shares, the actual short interest is closer to 100% of the tradable float. Look for a big pop in TXMD is the short squeeze happens, if not, it will still be a 2-3X within 12 months.
    :
    - Clovis Oncology, Inc.: Ticker “CLVS”:
    Currently trading at $8.91, CLVS is one of the top stocks on the NASDAQ. CLVS is presenting updates on their oncology(cancer) drug on February 8th. We expect good results and a squeeze to take place shortly thereafter. Institutions hold 61%+ with Blackrock recently increasing their holdings significantly. Also, 42% of the float is short so this could be a big mover next week.
    - Precigen, Inc.: Ticker “PGEN”:

    Curently trading at $7.95, Precigen may be one of the most overlooked stock and short plays in the US. The recently closed on a Public Offering of 17,250,000 @ $7.50 giving them gross proceeds of $129.4 million. Some of the biggest institutions participated in that financing, showing a lot of support in the company. 80% of the Float is owned by institutions, while insiders own another 18% or 98-99% of the float held by long term investos. With 35% of the float being short, in our opinion, the tradeable float well over 100% and this could be another GME scenario as their innovative gene and cell therapies are world class. Also, they are presenting at the Guggenheim Healthcare Talks Oncology Day on Friday, February 12, 2021.

    This is not financial advice, while we believe in our Due Diligence, please do your own before you invest. If you agree with out post, please upvote it and even share it to the main WSB thread as our old account has been hacked and we had to open a new one which is not able to post until the 30-45 day period.

    Save Companies, take down the shorts. #YOLO

    KillerB - #STRENGTHINNUMBERS
  • J
    John
    $TCNNF conversation
    Here is another link to the largest short positions on the CSE... Trulieve (and other MSOS) are at the top. Around 30,000,000 shares shorted on Trulieve with around 30% total short interest. Trulieve had a volume of just 200,000 today. TWO HUNDRED THOUSAND. You do the math and see how bazaar/unreal these numbers are for businesses of an amazing stature.

    https://shortdata.ca/largest-short-positions

    There are also other sources that all restate the same findings found on this webpage.

    Then again, these business (MSOs) are not shorted because of poor fundamentals. They are shorted because traders with an excess of capital take advantage of the fact that Trulieve (and other MSOs) are trading on the illiquid OTC market, which means that there is a very low amount of volume being put into these stocks. Because of this, short traders are able to manipulate the market and put in huge short orders with out much of a fight back from longs.

    You may ask, why aren't other companies on the CSE also heavily shorted, considering they are on the same Canadian exchange? The reasoning is because most other companies listed on the CSE are also part of the NYSE, Nasdaq or European markets, which are very liquid exchanges that see lots of volume. Trulieve and other MSOs are in a unique position, being permitted to list on the CSE, but not American markets. The basic and simple reasoning for this is because marijuana is federally legal in Canada, but not the US. The USA does not let businesses that partake in the sale of federally illegal drugs on their main exchanges. In addition to this, most companies that have heavy short interest are companies that are experiencing a declining industry, declining revenue/earnings, and/or sharply declining business fundamentals. Trulieve and other MSOs are the polar opposite of all these reasons. The only reason why MSOs are shorted, is because they are listed and manipulated on illiquid markets. Nothing more, and nothing less.

    So what does this mean for investors? Among analysts, Trulieve has an average upside of over 185% from its current valuation, which in my opinion, is very conservative. Other MSOs also have an unbelievable upside. Investors need to understand that the fundamentals of MSOs are ever so strong, with Trulieve likely having the most attractive valuation compared to other MSOs, and investors need to maintain a long term view in spite of the recent negative market sentiment.

    The biggest catalyst that will bring the stock price up in the near future, is any hope or progression of an up-listing to a major exchange. No one knows when this will happen (many people believe it should have happened by now), but it is basically definite and inevitable that an up-list will certainly occur sometime in the near future. In addition, once MSOs become federally accepted and receive some sort of relief, the tax code 280e will likely be removed as well, which will dramatically accelerate the profits of all MSOs alike. These two catalysts in particular should see the stock prices of these MSOs rise a significant amount, and that is not even factoring in the ever so strong fundamentals that these companies possess.

    Overall, investors in the MSO industry need to stay confident in their decisions and maintain a long-term outlook on these businesses, and ignore the artificial obstacles that exist for the current and near-term future.

    $TCNNF $GTBIF $CURLF $CRLBF $AYRWF $MSOS $YOLO $IIPR
    Home - Shortdata.ca
    shortdata.ca
  • k
    ken d
    #YOLO seems to more diverse in their investments, also a higher percentage in US cannabis. I bought 200 shares @26.75 plan on holding this one, wish I got in earlier bought #MMNFF a couple years ago.😫😫😫
  • a
    art
    Why dropping?
  • j
    jj
    $TCNNF conversation
    $CNBS, $MSOS, $YOLO, $AYRWF, $CCHWF, $CNTMF, $CRLBF, $CURLF, $GTBIF, $HRVSF, $JUSHF, $TCNNF, $TRSSF, from today’s editionmof Mew Cannabis Ventures…
    Earnings season for American cannabis companies is off to a fantastic start. We heard from some of the largest operators and ancillary companies this past week, and they all provided strong near-term results. While the revenue growth rates remain impressive, what is really capturing our attention is how much more efficient these companies have become, resulting in bottom-line growth that is far exceeding expectations.

    With four of the leading MSOs and two of the leading ancillary companies that reported, here is how revenue, gross profit and SG&A changed in Q1 compared to a year ago along with the change in operating margin:

    Curaleaf, which reported revenue ahead of the consensus of $253 million, saw cash SG&A grow at 75%, well below the revenue growth rate, helping the operating margin expand 1900 bps. Green Thumb Industries, which reported entirely organic revenue growth, also exceeded expectations of $187 million. It boosted its operating margin by 1900 bps as well, with most of the gain coming from substantially lower SG&A relative to revenue. Trulieve, which also beat expectations of $189 million, was the only company to see gross profit grow more slowly than revenue, which was due to its entry into Pennsylvania. Its gross margin and operating margin remain at the top of the industry.

    Hydrofarm was able to expand gross profit substantially more than its revenue growth and saw cash operating expenses grow significantly slower. Its operating margin expanded by 570 bps. GrowGeneration slightly expanded its gross margin but benefitted from significantly slower growth in its operating expenses. The company breaks out corporate SG&A, which was up just 5%, from store operations, which grew 125%. Finally, Harvest had the most impressive swing, with gross margin expanding significantly as cash SG&A actually declined despite a doubling in sales. The operating margin expanded by 7160 bps.

    The largest American cannabis companies delivered impressive results in Q1, demonstrating that they are rapidly scaling and improving profitability. We discussed last week that weakness in large Canadian LP stocks has been weighing on the American stocks, and the news this week from Aurora Cannabis and Tilray, who are struggling with the adult-use market in Canada, pushed their stocks even lower. The MSOs that reported last week generally fared better than the New Cannabis Ventures Global Cannabis Stock Index, which fell 8.2%. Harvest, of course, rallied on the acquisition announcement:

    While cannabis stocks continued to correct last week, led by large Canadian LPs, we didn't see anything in the reports of leading American companies that would suggest any sort of fundamental reasons for concern. We will still be getting reports from several MSOs over the balance of May, and there aren't any reports from large LPs until Canopy Growth reports in early June. Continued reports of strong execution from MSOs in the absence of negative reports from the largest Canadian LPs could capture investor attention in the weeks ahead.
  • B
    Bear Ridge
    I bought YOLO today. I thought it was a better buy then MSOS.
    It has plenty of exposure to the US market. And it pays Divs.
    https://advisorshares.com/etfs/yolo/
  • J
    Jay
    Can someone explain the difference between yolo, cnbs and mj? which etf has the best results? tried looking up and cant seem to decide. Looking for aggressive growth (3monts-2 years)
  • N
    Nolan
    We are in an ascending pennant, which is a continuation pattern. Let’s aim to break out of previous highs.